Accès gratuit
Med Sci (Paris)
Volume 23, Numéro 4, Avril 2007
Page(s) 423 - 427
Section M/S revues
Publié en ligne 15 avril 2007
  1. Lowy DR, Howley PH. Papillomaviruses. In : Knipe DM, Howley PH, eds. Fields virology. Philadelphia, Pennsylvania, USA : Lippincott, Williams and Wilkins, 2001 : 2231–64. [Google Scholar]
  2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 : 518–27. [Google Scholar]
  3. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen ? The international perspective. Int J Cancer 2004; 111 : 278–85. [Google Scholar]
  4. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91 : 942–53. [Google Scholar]
  5. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109 : 418–24. [Google Scholar]
  6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 : 12–9. [Google Scholar]
  7. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185 : 251–7. [Google Scholar]
  8. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet 2004; 364 : 1757–65. [Google Scholar]
  9. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347 : 1645–51. [Google Scholar]
  10. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6 : 271–8. [Google Scholar]
  11. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107 : 18–27. [Google Scholar]
  12. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75 : 2075–9. [Google Scholar]
  13. Roden RB, Hubbert NL, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70 : 3298–301. [Google Scholar]
  14. Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine 2006; 24 (suppl 3) : S114–21. [Google Scholar]
  15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomised control trial. Lancet 2006; 367 : 1247–55. [Google Scholar]
  16. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 : 1459–66. [Google Scholar]
  17. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118 : 2135–45. [Google Scholar]
  18. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24 : 5571–83. [Google Scholar]
  19. Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 : a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005; 80 : 601–10. [Google Scholar]
  20. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance: United States, 2003. MMWR Surveill Summ 2004; 53 : 1–96. [Google Scholar]
  21. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157 : 218–26. [Google Scholar]
  22. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13 : 631–9. [Google Scholar]
  23. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188 : 555–63. [Google Scholar]
  24. Weller TH. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med 1953; 83 : 340–6. [Google Scholar]
  25. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology, and health impact in children. Pediatr Infect Dis 1984; 3 : 505–9. [Google Scholar]
  26. Leclair JM, Zaia JM, Levin MJ, et al. Airborne transmission of chickenpox in a hospital. N Engl J Med 1980; 302 : 450–3. [Google Scholar]
  27. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58 : 9–20. [Google Scholar]
  28. Gershon A, Steinberg S, Borkowsky W, et al. Subclinical zoster: identification by serum IgM to varicella-zoster virus. Pediatr Res 1981; 15 : 610. [Google Scholar]
  29. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347 : 340–6. [Google Scholar]
  30. Oxman MN. Clinical manifestations of herpes zoster. In : Arvin AM, Gershon AA, eds. Varicella zoster virus : virology and clinical management. Cambridge, England : Cambridge University Press, 2000 : 246–75. [Google Scholar]
  31. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61 : 310–6. [Google Scholar]
  32. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62 : 1545–51. [Google Scholar]
  33. D workin RH, Schmader KE. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36 : 877–82. [Google Scholar]
  34. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335 : 32–42. [Google Scholar]
  35. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J lnfect Dis 1992; 166 : 1153–6. [Google Scholar]
  36. Weller TH. Varicella and herpes zoster : changing concepts of the natural history, control and importance of a not-so-benign virus (part two). N Engl J Med 1983; 309 : 1434–40. [Google Scholar]
  37. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 : 370–5. [Google Scholar]
  38. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2 : 1288–90. [Google Scholar]
  39. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18 : 70–80. [Google Scholar]
  40. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing safety profile of varicella. Vaccine 2001; 19 : 916–23. [Google Scholar]
  41. Vazquez M, LaRussa P, Gershon A, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344 : 955–60. [Google Scholar]
  42. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 : 2271–84. [Google Scholar]
  43. Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 2007; 25 : 1877–83. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.